key: cord-0925128-riqfc7u4
authors: Gu, Chunyin; Cao, Xiaodan; Wang, Zongda; Hu, Xue; Yao, Yanfeng; Zhou, Yiwu; Liu, Peipei; Liu, Xiaowu; Gao, Ge; Hu, Xiao; Zhang, Yecheng; Chen, Zhen; Gao, Li; Peng, Yun; Jia, Fangfang; Shan, Chao; Yu, Li; Liu, Kunpeng; Li, Nan; Guo, Weiwei; Jiang, Guoping; Min, Juan; Zhang, Jianjian; Yang, Lu; Shi, Meng; Hou, Tianquan; Li, Yanan; Liang, Weichen; Lu, Guoqiao; Yang, Congyi; Wang, Yuting; Xia, Kaiwen; Xiao, Zheng; Xue, Jianhua; Huang, Xueyi; Chen, Xin; Ma, Haixia; Song, Donglin; Pan, Zhongzong; Wang, Xueping; Guo, Haibing; Liang, Hong; Yuan, Zhiming; Guan, Wuxiang; Deng, Su-Jun
title: A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
date: 2021-06-07
journal: mAbs
DOI: 10.1080/19420862.2021.1930636
sha: fa4b19d545f4ea906bb3a9ab72a4d5f2e3c4a00e
doc_id: 925128
cord_uid: riqfc7u4

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.

Coronavirus disease-2019 (COVID- 19) , which is caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was first reported at the end of 2019 and has spread worldwide as a severe pandemic. 1 As of March 2, 2021, the World Health Organization (https://www.who.int) has received reports of 114,140,104 confirmed cases including 2,535,520 deaths. Of much more public health concern, numerous variants of SARS-CoV-2 continue to emerge, some of which are reported to have enhanced transmissibility or reduced protective effect by vaccines. 2 Such strains include South African variant B.1.351 and UK variant B.1.1.7, which spread faster than the SARS-CoV-2 prototype and have aroused even more concerns all over the world.

To date, no typical therapies or repurposed drugs have shown the desired efficacy in treating COVID-19; 3 however, monoclonal antibodies (mAbs) are a potentially effective therapeutic option. The safety and potency of human antibodies targeting viral surface proteins have been demonstrated in multiple clinical trials investigating infectious diseases such as Ebola, 4,5 SARS, 6, 7 and Middle East respiratory syndrome (MERS). 8 Recently, the U.S. Food and Drug Administration issued emergency use authorizations for combination mAb therapies bamlanivimab and etesevimab (Lilly) and casirivimab and imdevimab (Regeneron) for the treatment of mild-to-moderate COVID-19 (https://www.fda.gov/ emergency-preparedness-and-response/mcm-legal-regulatoryand-policy-framework/emergency-use-authorization).

Because SARS-CoV-2 infection is initiated by attachment of the spike (S) glycoprotein on the viral surface to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell via the viral receptor-binding domain (RBD), 9 antibodies that target the RBD are hypothesized to have potent neutralizing activity. SARS-CoV-2 RBD neutralizing antibodies (nAbs) have been isolated from B cells of convalescent patients via single-cell sequencing. [10] [11] [12] [13] However, despite the ability of single-cell sequencing to quickly identify thousands of antigenbinding sequences, tremendous effort is required to produce and profile hundreds or even thousands of recombinant antibodies to obtain nAbs with the desired properties. [10] [11] [12] [13] By contrast, we applied a phage-to-yeast (PtY) platform 14 that combines the advantages of phage display 15, 16 and yeast display 17 to precisely and efficiently identify the desired nAbs from naïve human B cell antibody libraries.

Accordingly, in this study, we report the rapid identification of two potent nAbs against SARS-CoV-2 from our naïve phage-displayed human B cell single-chain variable fragment (scFv) libraries using a PtY platform. The most potent antibody, JMB2002 (Ab2001.08 N297A), not only showed potent in vitro blocking activity against a broad-spectrum of SARS-CoV-2 variants including the B.1.351 lineage, but also potent therapeutic efficacy and complete prophylactic protection against SARS-CoV-2 in a rhesus macaque infection model.

The PtY platform was used to quickly identify potential clones with neutralizing activity against SARS-CoV-2 ( Figure 1 ). First, we screened and enriched binders with biotinylated SARS-CoV -2 RBD protein in solution using an in-house naïve phagedisplayed human B cell scFv library (library size: 2.8 × 10 10 ). Subsequently, yeast-displayed scFv libraries were constructed from enriched phage scFv display outputs with more than 10fold coverage to maintain diversity. Specifically, we added hACE2 to a mixture of the yeast display library and the SARS-CoV-2 RBD protein to select clones with potential hACE2neutralizing activity in solution. After fluorescence-activated cell sorting (FACS) and sequencing, 117 potential neutralizing clones with unique sequences were identified, and the sequences of these clones were analyzed to avoid those with potential posttranslational modification motifs, which may affect antibody function and stability. Thirty-four clones from the naïve phage display library were selected for further characterization.

To confirm the specificity of these clones, their ability to bind to the SARS-CoV-2 RBD and to two nonrelated control proteins and their ability to block the binding of the SARS-CoV -2 RBD to hACE2 were tested. Ten clones from the naïve phage display library were identified, and the corresponding mAbs were produced in mammalian cells. We next used biolayer interferometry (BLI) to determine the affinity of selected and purified mAbs toward the SARS-CoV-2 RBD. As shown in Table 1 , five of the 10 antibodies from the naïve phage display library bound to the SARS-CoV-2 RBD with high affinity, indicating that the PtY platform successfully identified highaffinity SARS-CoV-2 RBD-binding mAbs. Figure 1 . Identification of neutralizing antibodies with a PtY display platform. We first used our preconstructed naïve phage displayed human scFv library to screen binders with biotinylated SARS-CoV-2 RBD protein in the solution phase. After enrichment of phage binders, the scFv DNA from enriched binders was cloned into the yeast display plasmid, resulting in display of scFv on the yeast cell surface. We then performed FACS to isolate potential blocking antibodies that could prevent binding of the SARS-CoV-2 RBD to hACE2. The 0.013% gate contained blocking antibodies with high affinity toward RBD. That is, higher Y axis signal represented higher affinity to labeled RBD, whereas lower X signal represented higher potency in blocking the binding of differently labeled hACE2 to RBD. The potential blocking antibodies were sent for sequencing and transient expression. The purified antibodies were evaluated for affinity, blocking activity, biophysical properties, and virus-neutralizing activity. 

To evaluate the neutralization ability of the antibodies with specific and strong SARS-CoV-2 RBD-binding activity, we used enzyme-linked immunosorbent assay (ELISA) to test their ability to block SARS-CoV-2 RBD-hACE2 binding. Among the antibodies tested, Ab2001.08 and Ab2001.10 most potently blocked the binding of the SARS-CoV-2 RBD to hACE2 (Figure 2a) . Moreover, to determine whether these lead mAbs recognize the same or different RBD epitopes, an epitope binning experiment using BLI was performed, which demonstrated that Ab2001.08 and Ab2001.10 were grouped in different epitope bins (Figure 2b) . These results showed that the PtY platform precisely identified potent antibodies that blocked RBD binding to hACE2.

To measure the SARS-CoV-2-neutralizing capability of those antibodies, a live SARS-CoV-2 assay was performed by measuring the viral load 24 h after virus infection by quantitative real-time reverse transcription-PCR (qRT-PCR). Compared to an irrelevant IgG control, Ab2001.08, Ab2001.09, Ab2001.10, and Ab2001.08+Ab2001.10 resulted in a greater than 2 log reduction in the viral load at 24 h after infection (Table 1 ). These results indicated that these antibodies exhibited live virus-neutralizing activity.

To compare the potency of Ab2001.08 and Ab2001.10, which showed the most promising activity in inhibiting virus replication, we performed plaque reduction neutralization tests (PRNTs) using SARS-CoV-2. Ab2001.08 and Ab2001.10 showed PRNT 50 values of 12 and 62 ng/ml, respectively ( Figure 2c ).

To select a candidate with the lowest risks for manufacturing, physicochemical properties were evaluated. Ab2001.08 displayed desired chemistry, manufacturing, and controls (CMC) manufacturability (Table 2) 18 and higher virus neutralization potency than Ab2001.10. Therefore, we selected Ab2001.08 as the lead antibody for further development. Immunogenicity is also critical in the process of therapeutic antibody development. 19, 20 Repeated dosing of a therapeutic protein can lead to B-cell activation, which is triggered by T cell-recognition of peptide epitopes displayed on major histocompatibility complex class II (MHCII) proteins on the surface of mature antigen-presenting cells, resulting in the production of anti-drug antibodies (ADAs). ADAs can influence drug clearance and/or therapeutic efficacy. To predict potential immunogenicity risk, in silico analysis of antibody variable region gene sequences was performed using an inhouse developed algorithm to assess potential T-cell epitopes. The algorithm serves as a ranking tool, with a lower value indicating lower immunogenicity. By this algorithm, Ab2001.08 was predicted to show low immunogenicity compared to that of some marketed therapeutic antibodies (Table  3) . Additionally, JMB2002 has a comparable somatic hypermutation rate (SHM) ( Table 4 ) compared to nAbs isolated from convalescent COVID-19 patients, suggesting low potential immunogenicity of this antibody.

Overall, our data showed that potent nAbs with diverse epitopes and good developability could be identified by the PtY platform ( Figure 1) .

Antibody-dependent enhancement (ADE) is a side-effect of nAbs in which anti-virus antibodies enhance the entry of viruses into immune cells expressing Fc receptors (FcRs). To reduce the potential risk of ADE by reducing the interaction of the antibody with Fc receptors, we introduced the N297A mutation 21 into the Fc region of Ab2001.08, yielding Ab2001.08 N297A (JMB2002). Antibody binding to FcRs was evaluated by BLI. Ab2001.08, with wild-type human IgG1, bound to human FcγRI, FcγRIIA (R/H167), and FcγRIIIA (F/V176) with K D values similar to published values 22 ( Figure  3a and Table S1 ). After Fc modification, JMB2002 could still bind to FcγRI (CD64), with an affinity approximately 9-fold lower than that of Ab2001.08, whereas its binding ability to FcγRIIA (R/H167) and FcγRIIIA (F/V176) was markedly reduced (Figure 3a and Table S1 ).

To evaluate ADE activity, we infected Fcγ receptorengineered cell lines with SARS-CoV-2 pseudovirus in the presence of antibodies. Consistent with the binding affinity of the antibodies to FcγRI, Ab2001.08 mediated greater virus infection in the FcγRI-engineered cell line than did JMB2002 ( Figure 3b ). As expected, no ADE effect was observed for the control antibody trastuzumab (Herceptin). Moreover, because JMB2002 binds only weakly to FcγRIIA and FcγRIIIA, the ADE effect was abolished for JMB2002 when FcγRIIA H167and FcγRIIIA V176-engineered cell lines were used as target cells, whereas Ab2001.08 retained its ADE activity (Figure 3c , d). The antibody-dependent cellular cytotoxicity (ADCC) effect of JMB2002 was also abolished when the ADCC reporter cell line was used as an effector cell (Fig. S1 ). In summary, Fcmodified JMB2002 reduced ADE activity in the FcγRIexpressing cell line and eliminated the ADE effect in the FcγRIIA H167-and FcγRIIIA V176-expressing cell lines, indicating that JMB2002 may have a good safety profile in vivo.

To further study the neutralizing ability of JMB2002, we first determined its binding affinity for SARS-CoV-2 S proteins by BLI. JMB2002 bound to the SARS-CoV-2 RBD with a K D of approximately 3.33 nM and to the tested SARS-CoV-2 RBD variants with a K D in the single-digit nM range (Figure 4a and Table S2A ). The binding of JMB2002 to a double-mutant RBD (N354D/D364Y) and a mutant RBD (L452R) was decreased approximately 3.5-and 65-fold, respectively, compared with its binding to a prototype RBD (Figure 4a and Table S2A ). JMB2002 also bound to SARS-CoV-2 S1 (D614G), a currently widespread strain with increased infectivity, with a K D of 11.9 nM. Moreover, the binding affinity was similar to that for SARS-CoV-2 S1 (Figure 4b and Table S2B ). We also assessed the binding activity of JMB2002 to recently emerged SARS-CoV-2 variants from UK and South Africa. Encouragingly, JMB2002 showed 1.9-and 6.8-fold higher affinity to the UK and South African variants when compared to S1 prototype, respectively ( Figure 4b and Table S2B ). These results demonstrated that JMB2002 could bind to a broad range of SARS-CoV-2 RBD variants with high affinity, indicating that this mAb has broad-spectrum activity against SARS-CoV-2 strains. The binding specificity of JMB2002 was also evaluated. The results showed that JMB2002 specifically bound to SARS-CoV-2 RBD protein (Fig. S2A ) and SARS-CoV-2 spike protein overexpressed on HEK293 cells (Fig. S3A) . Characterization of potential blocking antibodies. (a) Blocking assay was performed by immobilizing 1 µg/ml hACE2 on a plate. Serially diluted antibodies and biotinylated SARS-CoV-2 RBD protein were added for competitive binding to hACE2. IC 50 values were calculated with Prism V8.0 software using a four-parameter logistic curve fitting approach. (b) Epitope binning was carried out by BLI. Biotinylated SARS-CoV-2 RBD was immobilized onto the SA sensor, and a high concentration of the primary antibody was used to saturate its own binding site. Subsequently, a second antibody was applied to compete for the binding site on the SARS-CoV-2 RBD protein. Data were analyzed with Octet Data Analysis HT 11.0 software. (c) Neutralization activities of Ab2001.08 and Ab2001.10 were assessed by live virus assay. Live SARS-CoV-2 and serially diluted (3-fold) antibodies were added to VERO E6 cells. The PRNT 50 values were determined by plotting the plaque number (neutralization percentage) against the log antibody concentration in Prism V8.0 software.

Unsurprisingly, JMB2002 displayed no binding activity to SARS-CoV RBD protein (Fig. S2B ), MERS-CoV RBD protein (Fig. S2C ), and HEK293 cells (Fig. S3B) .

We next performed ELISA to test the blocking activity of JMB2002. JMB2002 blocked the binding of SARS-CoV-2 S proteins to hACE2 to different extents (Figure 4c, d and Table S2A , B). Specifically, JMB2002 displayed decreased blocking activity toward the V483A, A475V, and L452R mutant RBDs by approximately 2-, 4.4-, and 42-fold, respectively, compared to that of the RBD prototype ( Figure 4c and Table S2A ). In addition, the blocking effect of JMB2002 on the N354D/D364Y and W436R RBDs was approximately 1.7-and 4.3-fold, respectively, stronger than that on the RBD prototype ( Figure 4c and Table  S2A ). Although hACE2-Fc prevented the SARS-CoV-2 RBD from binding to hACE2, it was approximately 67-fold less potent than JMB2002 (Table 1 ), indicating that JMB2002 could be much more potent than hACE2-Fc for treating COVID-19. Notably, JMB2002 demonstrated potent blocking activity against the South African variant even at the cost of a 2.8-fold loss in potency when compared to that of S1 prototype ( Figure 4d and Table  S2B ). Interestingly, the blocking activity of JMB2002 toward the UK variant was decreased 17-fold ( Figure 4d and Table S2B ), although the binding activity increased by 1.9-fold ( Figure 4b and Table S2B ) as compared to S1 prototype. Moreover, the potency of JMB2002 was 12-fold and 3.4-fold higher than that of hACE2-Fc against the South African and UK variants, respectively (Fig.  S4 ). The activity of antibody CB6, which was included as a comparator, was impaired against the UK variant and markedly abolished against South African variant (Fig. S4 ).

To determine the neutralizing activity of JMB2002, we performed a pseudovirus neutralization assay in which the entry of pseudovirus into the hACE2-expressing cell line was correlated with an increased luciferase signal in the cells. JMB2002 and Ab2001.08 showed potent neutralization ability, with halfmaximal inhibitory concentration (IC 50 ) values of 4.25 and 5.09 ng/ml, respectively, against SARS-CoV-2 pseudovirus ( Figure 4e ). Additionally, Fc modification of Ab2001.08 had no effect on its neutralizing activity.

Based on the potent neutralizing activity and desired developability described above (Table 2) , we moved JMB2002 into the CMC development stage. The expression titer of the obtained CHO-K1 CMC clone was approximately 6 g/L. Additionally, the monomer and high molecular weight (HMW) level of JMB2002 (50 mg/ml) was 98.88% and 1.12%, respectively, as measured by size-exclusion chromatography-high performance liquid chromatography (SEC-HPLC), the Fab melting temperature (Tm) was 87.7°C, and the aggregation temperature (Tagg) was 64.5°C, suggesting the good manufacturability of JMB2002. Overall, our results suggested that JMB2002 is a broad-spectrum potent nAb with desired manufacturability.

To assess the ability of JMB2002 to treat viral infection and protect against viral challenge in vivo, we tested this antibody in rhesus macaques infected with SARS-CoV-2. In this experiment, rhesus macaques were assigned to three experimental conditions: one control animal was intravenously (IV) administered a single dose of irrelevant hIgG1 N297A (20 mg/kg) one day post-infection (dpi) with 1 × 10 5 50% tissue culture infectious dose (TCID 50 ) of SARS-CoV-2; the prophylactic group (n = 2) was intravenously administered 20 mg/kg JMB2002 one day before viral infection; and the therapeutic group (n = 2) was intravenously administered 50 mg/kg JMB2002 one day and three days after viral infection ( Figure  5a ). The viral load of oropharyngeal swab samples in the control group peaked at approximately 10 7 RNA copies/ml at 5 dpi (Figure 5b) . In contrast, a single dose of JMB2002 (20 mg/ kg) before infection provided complete prophylactic protection against SARS-CoV-2 infection, with no virus detected in oropharyngeal swab samples (under the detection limit of 200 copies/ml, Figure 5b ). In the therapeutic group, the viral RNA of one animal was reduced by approximately 3 logs compared with that of the control animal at 5 dpi ( Figure  5b) . Notably, the viral load of the other animal in the therapeutic group was reduced to less than the detection limit at 3 dpi ( Figure 5b ). These results suggested that JMB2002 can provide complete protection and potent therapeutic efficacy in vivo. In addition, no marked change in body weight, body temperature, and hematology was observed in each monkey during the study (Fig. S5 ). Because COVID-19 is predominantly a lung infection, we also examined the ability of JMB2002 to protect against lung damage from SARS-CoV-2 infection. All animals were sacrificed and necropsied at 7 dpi. Based on evaluation of pneumonia severity, the control animal was diagnosed with viral pneumonia with extensive pulmonary fibrosis, exhibiting pathology including thickened alveolar septa, fibroblast proliferation and fibrosis, and intensive monocyte and lymphocyte infiltration (Figure 5c ). In some alveolar cavities, cellulose exudation was observed, with hyaline membrane formation and pulmonary hemorrhage. By contrast, animals treated with JMB2002 before or after infection displayed very limited pathological lung damage characterized by an overall intact alveolar structure, reduced edema and the absence of hyaline membrane formation, with less fibrosis and less leukocyte infiltration than the control animal ( Figure 5c ). In summary, JMB2002 reduced infection-related lung damage in both the prophylactic and therapeutic animal groups, suggesting that JMB2002 is an effective therapeutic.

To rapidly develop therapeutic antibodies in response to SARS-CoV-2 infection, we applied a PtY platform to identify a potent nAb JMB2002 in a precise and efficient manner, suggesting that the PtY platform can meet the needs of an immediate response to a global pandemic by accelerating research and development of nAbs. PtY, a unique human mAb discovery platform, offers the following 5 advantages: 1) the ability to identify lead SARS-CoV-2 nAbs from a naïve scFv library without using B cells from COVID-19 convalescent patients; 2) the ability to isolate rare nAbs from the libraries containing over 10 10 antibody clones within 10 days; 3) the ability to maintain the native conformation of the RBD, antibodies, and hACE2 at their maximal levels, because all screens were performed in solution with the inclusion of hACE2 as a competitor, leading to maximum possible simulation of hACE2 by the antibody; 4) the ability to identify two highly potent mAbs with different epitopes by producing and profiling only 10 IgGs; and 5) the ability to monitor antibody expression levels in real time, an important criterion in CMC. In fact, the expression titer of JMB2002 was approximately 6 g/L in the CHO-K1 CMC clone. Based on published literature, 10−13 SARS-CoV-2 nAbs identified from B cells of convalescent COVID-19 patients via single-cell technologies often require the production and profiling of hundreds to thousands of antibodies, highlighting the advantages of the PtY approach.

ADE has been observed in dengue virus infection, 23, 24 and several reports have demonstrated that antibodies induced by the SARS-CoV S protein enhanced viral entry into Fc receptorexpressing cells. 25, 26 To mitigate the potential risk of ADE, the N297A mutation was introduced into the Fc of JMB2002. Neutralization assays with pseudotyped SARS-CoV-2 confirmed the high potency of JMB2002, and Fc modification had no effect on its in vitro neutralizing activity. JMB2002 also displayed a complete protective effect and potent therapeutic efficacy in an in vivo nonhuman primate disease model, with substantially reduced lung tissue damage, suggesting that JMB2002 may have maintained a balance between attenuated Fc-mediated effector function such as antibody-dependent cellular phagocytosis (ADCP)-based viral clearance efficacy and reduced potential ADE risk. Different Fc modification strategies that involve either attenuating 13 or enhancing Fc effector function 27,28 have also been applied in the design of SARS-CoV-2 nAbs, some of which have moved into clinical trials. Our prospective goal is to have JMB2002 approved for the treatment of COVID-19, which will contribute not only to the treatment of SARS-CoV-2 infection, but also to the expansion of knowledge on the impact of Fc modification on the efficacy of antibody treatment of viral infection.

The lead antibody JMB2002 showed broad-spectrum activity against a range of SARS-CoV-2 RBD variants. It is generally accepted that mutations in amino acids of viral surface proteins can change the viral infectivity and/or reactivity of nAbs. A total of 329 naturally occurring SARS-CoV-2 S protein mutations have been reported worldwide, 29, 30 which has aroused interest concerning the impact of these variants on the COVID-19 Figure 4 . Characterization of JMB2002. Binding affinity of JMB2002 for the SARS-CoV-2 RBD (a)/S1 (b) prototype and its variants was determined by BLI. JMB2002 was loaded onto the AHC sensor, and serially diluted antigens were bound to JMB2002 on the biosensor. K D values were determined with Octet Data Analysis HT 11.0 software using a 1:1 global fit model. Blocking activity was assessed using ELISA with hACE2-coated plates. A mixture of biotinylated SARS-CoV-2 RBD (c)/S1 (d) proteins and JMB2002 was added for competitive binding to hACE2. IC 50 values were calculated by Prism V8.0 software using a four-parameter logistic curve fitting approach. Values are displayed as the mean ± standard deviations from three independent experiments. (e) The pseudovirus neutralization activity of JMB2002 was evaluated using a pseudotyped SARS-CoV-2 system, which contained a luciferase reporter. Pseudotyped viruses were preincubated with serially diluted antibodies for 1 h. The mixture was added to hACE2-expressing cells and incubated at 37°C for 20-28 h. Infection of cells with pseudotyped SARS-CoV-2 was assessed by measuring cellassociated luciferase activity. IC 50 values were calculated by plotting the inhibition rate against the log antibody concentration in Prism V8.0 software. pandemic and treatment approaches. A single D614G mutation outside the RBD region of the SARS-CoV-2 S protein, the predominant mutation worldwide, has been shown to confer increased infectivity in several studies. [31] [32] [33] Notably, our identified antibody JMB2002 not only bound to the SARS-CoV-2 S1 prototype and SARS-CoV-2 S1 (D614G) variant with similar affinity, but also exhibited improved potency in blocking the binding of SARS-CoV-2 S1 (D614G) to hACE2. Furthermore, three mutations, i.e., L452R, A475V, and V483A, have been shown to exhibit marked resistance to some antibodies. 29 Specifically, the neutralizing activity of antibodies B38, P2C-1F11, CB6, and 247 against A475V was decreased approximately 100-fold. Moreover, RBD L452R also reduced the sensitivity to antibodies X593 and P2B-2F6 and V483A to antibody X593 by approximately 100-fold. 29 In contrast, JMB2002 demonstrated only slightly decreased blocking ability for V483A and A475V compared to the RBD prototype. Similar to antibodies X593 and P2B-2F6, 29 JMB2002 also displayed resistance to L452R. Furthermore, JMB2002 exhibited increased binding to N354D/ D364Y and W436R. The recent emergence of new variants from UK (B.1.1.7 lineage) 34 and South Africa (B.1.351 lineage) 35 has caused concern because current nAb therapies or vaccines are not as effective against these variants. 36 The tested nAbs in clinical use or under clinical investigation showed comparable or slightly impaired efficacy against the UK variant when compared to D614G mutant. 36 Notably, the neutralizing activity of casirivimab (REGN10933), bamlanivimab (LY-CoV555) or the combination of LY-CoV555 and CB6 against the South African variant was markedly or completely abolished. JMB2002 retained potent blocking activity toward the South African variant, whereas the potency against the UK variant was 17-fold lower when compared to the S1 prototype. However, the potency of JMB2002 was 12-fold and 3.4-fold higher than that of hACE2-Fc against the South African and UK variants, respectively, indicating effective blocking of these two mutants by JMB2002. Collectively, these findings suggested the possibility of hACE2 receptor mimicry by JMB2002, indicating the potential ability of JMB2002 to exhibit broad-spectrum blocking activity against RBD mutants, an intuitive conclusion, since JMB2002 was identified by its ability to compete for hACE2 binding in solution.

The in vivo efficacy of JMB2002 was evaluated using a SARS-CoV-2 infected rhesus macaque model. The result showed that JMB2002 can provide complete protection and potent therapeutic efficacy in the animal disease model. The peak viral load of oropharyngeal swabs in the control group displayed a similar level with that in a rhesus macaque study of SARS-CoV-2 antibody CB6 and MW05/LALA. 13,37 CB6 and MW05/LALA also showed a complete prophylactic effect, as JMB2002 did. The viral titer of animal AC2 in the therapeutic group of JMB2002 reduced to less than the detection limit at 3 dpi, which was consistent with the declining trend in the therapeutic group of CB6 and MW05/LALA. Although the group size (n = 1 or 2) was small and variation in the therapeutic group was observed, the viral load in the therapeutic group showed notable reduction when compared to the negative control group, suggesting the potent in vivo efficacy of JMB2002. Moreover, the clinical trial (ChiCTR2100042150) is being conducted to further evaluate JMB2002. Encouraged by the successful clinical trial results of the anti-SARS-CoV-2 antibody cocktail from Regeneron and inspired by their studies suggesting that treatment with a combination of antibodies targeting non-competing epitopes prevented virus escape, 38 attempts to optimize the sequence of Ab2001.10 to increase its binding affinity for potential therapeutic application in combination with JMB2002 could be considered, since it recognizes a different epitope from JMB2002.

In conclusion, we report here the rapid discovery and development of anti-SARS-CoV-2 neutralizing antibody JMB2002. JMB2002 showed broad-spectrum in vitro neutralization activity toward multiple SARS-CoV-2 mutants including D614G, UK and South African variants. Moreover, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Currently, JMB2002 is undergoing evaluation in a clinical trial. Therefore, this antibody, alone or in combination with other therapeutics, could offer a potential therapy to prevent virus escape and subsequently contribute to the control of COVID-19 pandemic.

To obtain SARS-CoV-2 RBD-binding clones, we screened preconstructed human naive scFv phage libraries with biotinylated SARS-CoV-2 RBD (Sino Biological, 40592-V05H). Phage libraries were constructed using antibody gene fragments amplified from peripheral blood mononuclear cells (PBMCs) of 50 healthy human subjects (Allcells, PB003F and PB003 C) and total RNA from PBMCs (TaKaRa, 636592), spleens (TaKaRa, 636525), and bone marrow (TaKaRa, 636591) from 494 healthy human subjects. The phage selection was carried out in solution using 10 μg of biotinylated SARS-CoV-2 RBD protein (Sino Biological, 40592-V05H). Streptavidin (SA) magnetic beads (Thermo Fisher Scientific, Dynabeads M-280) were used to capture the phage binders that associated with the biotinylated antigen. After two rounds of phage selection to enrich for SARS-CoV-2 RBD binders, the phagemid DNA encoding the enriched scFv antibodies was prepared using QIAprep spin miniprep kit (Qiagen, 27104) and applied for the amplification of scFv sequences via PCR. The PCR product is compatible with our yeast display vector pJYY076 (modified from pYD1, Thermo Fisher Scientific). Therefore, the cloning was carried out by co-transferring the PCR product with the vector into Saccharomyces cerevisiae strain EBY100 (ATCC, MYA-4941) via electroporation, resulting in a yeast display scFv library. 39 We then developed a novel competitive FACS approach to rapidly identify potential blocking antibodies (Figure 1) . Specifically, the library was incubated with SARS-CoV-2 RBD containing a mouse Fc tag (Sino Biological, 40592-V05H), and biotinylated hACE2 (Kactus, ACE-HM401) was then added. Next, the libraries were labeled with SA-phycoerythrin (PE) (eBioscience, 12-4317-8) and goat anti-mouse-Alexa Fluor 647 antibodies (Thermo Fisher Scientific, A-21235). The population with a weak PE signal and a strong Alexa Fluor 647 signal was sorted in aFACSAria III (BD) to identify potential blocking antibodies with high RBD binding activity. The collected cells were sent for sequencing and further colony evaluation. The colonies with unique sequences were labeled with SA-PE and goat anti-mouse-Alexa Fluor 647 antibodies to confirm the hACE2 blocking potency. The colonies were also labeled with a biotinylated mouse Fc containing irrelevant antigen to confirm specific binding.

The full-length sequences of human IgG1 light and heavy chains of the candidate antibodies were codon optimized, synthesized, and cloned into an expression vector (GenScript). The antibody production was conducted by co-transfection of the light chain and heavy chain sequences into Expi293 cells according to the manufacturer's instructions (Thermo Fisher Scientific, A14635). The culture supernatant was collected at 7 days posttransfection, and protein purification was performed with Protein A magnetic beads (GenScript, L00695). The purified mAbs were dialyzed against phosphate-buffered saline (PBS) and kept for further analysis of biophysical properties and biological activities.

The affinity of mAbs for SARS-CoV-2 RBD/S1 and its mutants (750, 375, 187.5, 93.75, 46.88, 23.44, 11 .72 μg/ml) was evaluated in kinetics buffer for 3 min, except for association with FcγRΙ, which was evaluated in kinetics buffer at 37.5, 18.75, 9.38, 4 .69, 2.34, 1.17, and 0.59 μg/ml for 3 min. Dissociation in kinetics buffer was measured for 10 min. K D values were calculated with Octet Data Analysis HT 11.0 software using a 1:1 global fit model.

The blocking assay was performed using ELISA. Specifically, 1 μg/ml purified hACE2 protein (Kactus, ACE-HM501) was coated onto a 96-well ELISA plate (Thermo Fisher Scientific, 44-2404-21) at 4°C overnight. The next day, the plates were washed with washing buffer (PBS containing 0.05% Tween-20) and blocked with blocking buffer (2% BSA [Bovogen, BSAS 1.0] in washing buffer) at 37°C for 1 h. Four-fold serial dilutions of antibodies were preincubated with an equal volume of 0.5 μg/ml biotinylated SARS-CoV-2 RBD protein for 1 h at 37°C. The antigen/antibody mixtures were added to the plates and incubated at 37°C for 1 h. Subsequently, the plates were washed and incubated with 5000-fold diluted SA-horseradish peroxidase (Sigma, S2438). Tetramethylbenzidine substrate (Biopanda, TMB-S-003) was added for color development. The absorbance was measured at 450 nm using a spectrophotometer (Spectramax M3, Molecular Devices). IC 50 values were determined with Prism V8.0 software (GraphPad) using a fourparameter logistic curve fitting approach.

We conducted epitope binning of mAbs with an Octet Red96 (ForteBio, Sartorius) using an in-tandem format, in which mAbs competed against one another were in a pairwise combinatorial manner for binding to the SARS-CoV-2 RBD protein. Assays were performed at 30°C with continuous agitation at 1000 rpm. After obtaining an initial baseline in kinetics buffer, 1 μg/ml biotinylated SARS-CoV-2 RBD (Kactus, COV-VM4BD) was captured onto a SA biosensor (ForteBio, 18-5020) for 65 s. To saturate the binding sites for the first mAb on the SARS-CoV-2 RBD antigen, we exposed all sensors for 3 min to the first mAb (15 μg/ml) after immersion in kinetics buffer for 30 s. Then, we immersed the biosensors in kinetics buffer for 30 s and further immersed in wells containing a solution of the second mAb (15 μg/ml) for 3 min. Data analysis was performed with Octet Data Analysis HT 11.0 software using Epitope Binning mode.

The SARS-CoV-2 strain WIV04 (GenBank: MN996528.1) was obtained from the Wuhan Institute of Virology, Chinese Academy of Sciences. Vero E6 cells (ATCC, CRL-1586) were seeded in a 24-well plate (10 5 cells/well) and incubated at 37°C, in 5% CO 2 for 16 h. Subsequently, we added different mAbs (10 µg/ml) and then infected cells with SARS-CoV-2 at a multiplicity of infection of 0.005. Finally, we collected the cell culture supernatants after 24 h of infection for viral RNA extraction with a QIAamp 96 Virus QIAcube HT Kit (Qiagen, 57731) and for viral RNA copy number detection in a CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories). Data were processed using GraphPad Prism software (V8.0).

After the above initial screening for the ranking of 10 samples, based on reduced viral RNA copy numbers, PRNT assay was further performed to characterize the neutralizing activities of the most potent antibodies. We mixed 3-fold serially diluted mAbs (100 µl/well, starting from 30 µg/ml) and SARS-CoV-2 (WIV04) (100 µl/well, 2000 PFU/ml) into 96-well plates and incubated the mixtures for 30 min at 37° C. A well containing only the antibody was set up as an untreated control. Then, the antibody/virus mixture was added to a monolayer of Vero E6 cells and incubated at 37°C for 1 h. The plaques were counted after 96 h of viral infection. We determined the PRNT 50 values using a four-parameter logistic curve fitting approach (GraphPad Prism software V8.0).

SEC-HPLC was performed to quantify the monomer level of antibodies in a Waters Alliance 2695 HPLC system with a TOSOH TSKgel G3000W XL column (300 × 7.8 mm, 5 μm). The mobile phase was 200 mM sodium phosphate (pH 6.8), and the flow rate was 0.5 ml/min. Samples were assessed by measuring the UV absorbance at a wavelength of 280 nm. Data were analyzed with Waters Empower 3 Enterprise software (Waters, MA, USA).

Hydrophobic interaction chromatography (HIC)-HPLC was performed to evaluate the hydrophobicity of antibodies in a Waters Alliance 2695 HPLC system with a Thermo MAbPacHIC-10 column (4 × 250 mm, 5 μm). Mobile phase A consisted of 1 M ammonium sulfate with 50 mM sodium phosphate (pH 7.0), and mobile phase B consisted of 50 mM sodium phosphate (pH 7.0). Samples were injected and eluted with a linear gradient at a flow rate of 0.8 ml/min and the UV absorbance was measured at a wavelength of 214 nm. Data were analyzed with Waters Empower 3 Enterprise software. A shorter retention time indicated that the antibody had increased hydrophilicity. We used the retention times of omalizumab (14.2 min) and atezolizumab (Tecentriq) (26.8 min) as our standards, and the acceptance criterion was a retention time of less than 27 min.

The pI and charge variants were characterized by imaged capillary isoelectric focusing (iCIEF) in an iCE3 system (ProteinSimple, CA, USA). Samples were mixed with pharmalytes, 1% methyl cellulose, a pI marker and ddH 2 O to a final protein concentration of 0.2 mg/ml. Samples were pre-focused at 1500 V for 1 min and focused at 3000 V for 10 min, with detection at 280 nm. Data were acquired and analyzed with Chrom Perfect software (ProteinSimple Tagg is a thermal analysis parameter used to predict the thermodynamic stability of proteins, which can be characterized by dynamic light scattering (DLS) method. Measurements were performed on DynaPro Plate Reader II (Wyatt Technology). The samples were added into 384-well plate, centrifuged, and liquid sealed by paraffin oil. During the detection, samples were heated from 25°C to 75°C, and the data analysis was performed using DYNAMICS software provided by the vendor.

In silico analysis of antibody variable region gene sequences was performed using an in-house algorithm to assess potential T cell epitopes. The variable region gene sequences of marketed antibodies were retrieved from the international ImMunoGeneTics information system (IMGT) database (imgt.org). The variable region gene sequences of reference antibodies CB6 (PBD accession number: 7C01) and imdevimab (PBD accession number: 6XDG) were retrieved from the PDB database.

IMGT/V-QUEST and Domain Gap Align 40 were applied to analyze antibody gene germline, complementaritydetermining region (CDR)3 length, and somatic hypermutation (SHM). The CDR3 length was calculated from amino acid sequences (IMGT unique numbering). The SHM frequency was calculated from the mutated amino acids. The variable region gene sequences of reference antibodies CB6 (PBD accession number: 7C01) and imdevimab (PBD accession number: 6XDG) were retrieved from the PDB database.

The ADE effect of mAbs was measured by in vitro enhancement of infection by pseudotyped SARS-CoV-2 (National Institutes for Food and Drug Control, China) in CHO-K1 cells overexpressing FcγRI, FcγRIIA (H167) and FcγRIIIA (V176) (GenScript, M00588, M00598, and M00597). In brief, engineered CHO-K1 cells (100 μl/well) were seeded into 96-well plates at 5 × 10 5 cells/ml. Subsequently, pseudovirus (650 TCID 50 /well) and serial dilutions of mAbs (from 10 to 0.000013 μg/ml at four-fold dilutions) were preincubated for 1 h and then used to infect cultured cells at 37°C for 28 h. Trastuzumab (Roche) was used as the irrelevant IgG control. Infection of cells was evaluated by luciferase expression, as determined with a PE Britelite Plus Assay (PerkinElmer, 6066769), and the results were read on a luminometer (PerkinElmer). Enhancement of viral infection was evaluated by plotting the luciferase activity versus the antibody concentration in GraphPad Prism software (V8.0).

In the pseudovirus neutralization assay, serial dilutions of antibodies (from 10 to 0.000003 μg/ml at 4.5-fold dilutions) were preincubated with an equal volume of pseudovirus (650 TCID 50 /well) for 1 h at room temperature. Subsequently, CHO-K1 cells stably expressing hACE2 (WuXi Biologics) were seeded in 96-well plates (5 × 10 4 cells/well), treated with the pseudovirus and antibody mixtures, and incubated at 37°C for 20-28 h. Luciferase activity was measured using PE Britelite-Plus assay reagent (PerkinElmer, 6066769). The neutralization inhibition rate was calculated with the following formula: Inhibition rate % ð Þ ¼ 1 À mean intensity of sample mean intensity of negative control � À mean intensity of blank control À mean intensity ofblank control � � 100%

IC 50 values were calculated by a four-parameter logistic curve fitting approach in Prism V8.0 software (GraphPad).

Five 6-to 7-year-old rhesus macaques purchased from Topgene Biotechnology (Hubei, China) were housed and cared for in laboratory animal care-accredited facility. All animal experiments were approved by the Institutional Animal Care and Use Committee of Wuhan Institute of Virology, Chinese Academy of Sciences (Ethics no. WIVA42202006). All animals were anesthetized prior to sample collection, and experiments were carried out in the animal biosafety level 4 (ABSL4) laboratory.

All animals were randomly divided into three groups: the control group (one animal, C1), prophylactic group (two animals, PA1 and PA2), and therapeutic group (two animals, AC1 and AC2). PA1 and PA2 were injected intravenously with JMB2002 (20 mg/kg) one day before infection. Subsequently, all animals were inoculated intratracheally with SARS-CoV-2 (WIV04) at a dose of 1 × 10 5 TCID 50 . C1 was injected intravenously with irrelevant IgG (20 mg/kg) one day after infection, whereas AC1 and AC2 were injected with JMB2002 (50 mg/kg) one day and three days after infection. All animals were monitored along the timeline for recording of clinical signs and collection of oropharyngeal swabs. The animal experiment and sampling schedule are detailed in Figure 5a .

SARS-CoV-2 RNA was detected in swab samples by qRT-PCR. Total RNA was extracted with a QIAamp Viral RNA Mini Kit (Qiagen, 52906), and qRT-PCR was conducted with a HiScript® II One Step qRT-PCR SYBR® Green Kit (Vazyme, Q221-01). The qRT-PCR was performed in an ABI Real-time PCR System (Applied Biosystems). Amplification was carried out with the following thermal cycling program: 50°C for 3 min, 95°C for 30 s, and 40 cycles at 95°C for 10 s and 60°C for 30 s. The qRT-PCR primer pairs targeting the SARS-CoV-2 RBD were as follows: forward primer, 5ʹ-CAATGGTTAAGGCAGG-3ʹ; reverse primer, 5ʹ-CTCAAGGTCTGGATCACG-3ʹ.

Animal necropsies were performed according to a standard protocol at ABSL4. The animals were euthanized on day 7 post infection. The respiratory samples from each animal were collected for the histological analysis. Samples for histological examination were stored in 10% neutral-buffered formalin for 7 days, embedded in paraffin, sectioned and stained with hematoxylin and eosin or Masson's trichrome prior to examination by light microscopy. A researcher with more than 10 years' experience in the field analyzed the slides.

Angiotensin-converting enzyme 2 ADAs

Anti-drug antibodies ADCC Antibody-dependent cellular cytotoxicity ADCP Antibody-dependent cellular phagocytosis ADE Antibody-dependent enhancement AHC

Anti 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States

Repurposed antiviral drugs for COVID-19 -interim WHO solidarity trial results

Antibody-mediated protection against Ebola virus

Controlled Trial of Ebola Virus Disease Therapeutics

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Potent neutralizing antibodies e1930636-12

SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker

Making antibodies by phage display technology

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

Yeast surface display for screening combinatorial polypeptide libraries

Developability assessment during the selection of novel therapeutic antibodies

Improved methods for predicting peptide binding affinity to MHC class II molecules

T-cell epitopes with computational protein design

Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Cross-reacting antibodies enhance dengue virus infection in humans

Antibody-dependent enhancement of severe dengue disease in humans

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine proteaseindependent FcγR pathway

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity

Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

Spike mutation D614G alters SARS-CoV-2 fitness

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

An improved yeast transformation method for the generation of very large human antibody libraries

IMGT, the international ImMunoGeneTics information system

We thank all colleagues from the National Biosafety Laboratory (Wuhan), Chinese Academy of Sciences, for their support during the study. We also thank our colleagues from the Center for Instrumental Rectalysis and Metrology, Wuhan Institute of Virology, Chinese Academy of Sciences. We thank Dr. C. Roger MacKenzie for critical reading and editing of our manuscript.

The research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

http://orcid.org/0000-0002-3234-9616

C. G., X. C., Z. W., P. L., X. L., L. G., F. J., L. Y., N. L., G. J., J. Z., L. Y., M. S., T. H., Y. L., W. L., G. L., C. Y., Y. W., K. X., Z. X., J. X., X. H., X. C., Z. P., X. W., H. G., H. L., and S. D. were employed by Shanghai Jemincare Pharmaceuticals Co., Ltd. All other authors declare they have no potential conflicts of interests.